Literature DB >> 20448109

MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential.

Erica Ballabio1, Tracey Mitchell, Marloes S van Kester, Stephen Taylor, Heather M Dunlop, Jianxiang Chi, Isabella Tosi, Maarten H Vermeer, Daniela Tramonti, Nigel J Saunders, Jacqueline Boultwood, James S Wainscoat, Francesco Pezzella, Sean J Whittaker, Cornelius P Tensen, Christian S R Hatton, Charles H Lawrie.   

Abstract

MicroRNAs are commonly aberrantly expressed in many cancers. Very little is known of their role in T-cell lymphoma, however. We therefore elucidated the complete miRNome of purified T cells from 21 patients diagnosed with Sézary Syndrome (SzS), a rare aggressive primary cutaneous T-cell (CD4(+)) lymphoma. Unsupervised cluster analysis of microarray data revealed that the microRNA expression profile was distinct from CD4(+) T-cell controls and B-cell lymphomas. The majority (104 of 114) of SzS-associated microRNAs (P < .05) were down-regulated and their expression pattern was largely consistent with previously reported genomic copy number abnormalities and were found to be highly enriched (P < .001) for aberrantly expressed target genes. Levels of miR-223 distinguished SzS samples (n = 32) from healthy controls (n = 19) and patients with mycosis fungoides (n = 11) in more than 90% of samples. Furthermore, we demonstrate that the down-regulation of intronically encoded miR-342 plays a role in the pathogenesis of SzS by inhibiting apoptosis, and describe a novel mechanism of regulation for this microRNA via binding of miR-199a* to its host gene. We also provide the first in vivo evidence for down-regulation of the miR-17-92 cluster in malignancy and demonstrate that ectopic miR-17-5p expression increases apoptosis and decreases cell proliferation in SzS cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448109      PMCID: PMC2938132          DOI: 10.1182/blood-2009-12-256719

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.

Authors:  N Booken; A Gratchev; J Utikal; C Weiss; X Yu; M Qadoumi; M Schmuth; N Sepp; D Nashan; K Rass; T Tüting; C Assaf; E Dippel; R Stadler; C-D Klemke; S Goerdt
Journal:  Leukemia       Date:  2007-11-22       Impact factor: 11.528

2.  Dnm3os, a non-coding RNA, is required for normal growth and skeletal development in mice.

Authors:  Tokumitsu Watanabe; Takahiro Sato; Tomokazu Amano; Yumiko Kawamura; Naohiro Kawamura; Hiroshi Kawaguchi; Naohide Yamashita; Hiroki Kurihara; Takashi Nakaoka
Journal:  Dev Dyn       Date:  2008-12       Impact factor: 3.780

3.  Widespread microRNA repression by Myc contributes to tumorigenesis.

Authors:  Tsung-Cheng Chang; Duonan Yu; Yun-Sil Lee; Erik A Wentzel; Dan E Arking; Kristin M West; Chi V Dang; Andrei Thomas-Tikhonenko; Joshua T Mendell
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

4.  Novel and highly recurrent chromosomal alterations in Sézary syndrome.

Authors:  Maarten H Vermeer; Remco van Doorn; Remco Dijkman; Xin Mao; Sean Whittaker; Pieter C van Voorst Vader; Marie-Jeanne P Gerritsen; Marie-Louise Geerts; Sylke Gellrich; Ola Söderberg; Karl-Johan Leuchowius; Ulf Landegren; Jacoba J Out-Luiting; Jeroen Knijnenburg; Marije Ijszenga; Karoly Szuhai; Rein Willemze; Cornelis P Tensen
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

5.  MicroRNA-373 induces expression of genes with complementary promoter sequences.

Authors:  Robert F Place; Long-Cheng Li; Deepa Pookot; Emily J Noonan; Rajvir Dahiya
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-28       Impact factor: 11.205

6.  An Argonaute transports siRNAs from the cytoplasm to the nucleus.

Authors:  Shouhong Guang; Aaron F Bochner; Derek M Pavelec; Kirk B Burkhart; Sandra Harding; Jennifer Lachowiec; Scott Kennedy
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

7.  Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.

Authors:  W M Grady; R K Parkin; P S Mitchell; J H Lee; Y-H Kim; K D Tsuchiya; M K Washington; C Paraskeva; J K V Willson; A M Kaz; E M Kroh; A Allen; B R Fritz; S D Markowitz; M Tewari
Journal:  Oncogene       Date:  2008-02-11       Impact factor: 9.867

8.  MicroRNA expression in lymphocyte development and malignancy.

Authors:  C H Lawrie; N J Saunders; S Soneji; S Palazzo; H M Dunlop; C D O Cooper; P J Brown; X Troussard; H Mossafa; T Enver; F Pezzella; J Boultwood; J S Wainscoat; C S R Hatton
Journal:  Leukemia       Date:  2008-01-10       Impact factor: 11.528

9.  The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition.

Authors:  Nicole Cloonan; Mellissa K Brown; Anita L Steptoe; Shivangi Wani; Wei Ling Chan; Alistair R R Forrest; Gabriel Kolle; Brian Gabrielli; Sean M Grimmond
Journal:  Genome Biol       Date:  2008-08-14       Impact factor: 13.583

Review 10.  MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy?

Authors:  Charles Henderson Lawrie
Journal:  J Cell Mol Med       Date:  2008-07-08       Impact factor: 5.310

View more
  50 in total

Review 1.  MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development.

Authors:  Katie Podshivalova; Daniel R Salomon
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

2.  Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase.

Authors:  Katia Ruggero; Alessandro Guffanti; Alberto Corradin; Varun Kumar Sharma; Gianluca De Bellis; Giorgio Corti; Angela Grassi; Paola Zanovello; Vincenzo Bronte; Vincenzo Ciminale; Donna M D'Agostino
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 3.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

Review 4.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

Review 5.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

6.  How microRNAs modify protein production.

Authors:  Jessica L Feig; Keith M Giles; Iman Osman; Andrew G Franks
Journal:  J Invest Dermatol       Date:  2015-05       Impact factor: 8.551

Review 7.  Sézary Syndrome: Clinical and Biological Aspects.

Authors:  Rebecca Kohnken; Stephanie Fabbro; Justin Hastings; Pierluigi Porcu; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

8.  Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab.

Authors:  Haifeng Zhao; Le Zhang; Shanqi Guo; Tian Yuan; Bing Xia; FuLian Qu; Lianyu Zhang; Yizhuo Zhang
Journal:  Med Oncol       Date:  2014-09-07       Impact factor: 3.064

9.  The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.

Authors:  Mariyam Zuberi; Imran Khan; Gauri Gandhi; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2016-03-07

10.  Aberrant microRNA expression in tumor mycosis fungoides.

Authors:  E Papadavid; M Braoudaki; M Bourdakou; A Lykoudi; V Nikolaou; G Tounta; A Ekonomidi; E Athanasiadis; G Spyrou; C Antoniou; S Kitsiou-Tzeli; D Rigopoulos; A Kolialexi
Journal:  Tumour Biol       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.